The acquisition aims to create a broad product portfolio with significant offerings in automated dispensing systems, central pharmacy robotics, IV robotics and enterprise analytics.
The combined company supports approximately 4,000 acute care facilities worldwide, have annual revenues of over $650m and approximately 2,200 employees.
Founded in 1992 and led by Chairman, President and CEO, Omnicell is a supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum — from the acute care hospital setting to post – acute skilled nursing and long-term care facilities to the home.
It serves more than 3,000 customers worldwide via Omnicell Automation and Analytics solutions that aim to increase operational efficiency, deliver actionable intelligence and improve patient safety. The Omnicell Medication Adherence solutions, including the MTS Medication Technologies brand, provide medication adherence packaging products to help reduce hospital readmissions.
Led by Kraig McEwen, CEO, Aesynt provides a suite of automated and semi-automated solutions for the IV room including hazardous and non-hazardous solutions with IV workflow, compounding software and IV preparation analytics, central pharmacy solutions: including unit dose medication dispensing robots, vertical storage and dispensing of medications, open shelf inventory tracking and unit dose repackaging products and services, Point of Care solutions including medication storage and dispensing cabinets for nursing units and operating rooms and narcotic medication storage and dispensing and dynamic, enterprise-wide medication logistics management software, automated procurement and order management, and reporting and analytics for inventory management and medication utilization.
The company recorded approximately $182m of revenue and approximately $20m of adjusted EBITDA (unaudited) in the last twelve months ended June 30,
2015.
*The total aggregate consideration of the deal is $275m, in cash, plus cash on hand at signing minus indebtedness at signing, or approximately $217.3m, subject to certain adjustments at closing as provided for in the securities purchase agreement.
To finance the transaction, Omnicell will use cash available on its balance sheet and proceeds from $300m in senior secured credit facilities from Wells Fargo Securities, LLC and Wells Fargo Bank, N.A.
FinSMEs
01/11/2015